Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Oct 14;53(19):7067-75.
doi: 10.1021/jm100691c.

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain

Affiliations
Comparative Study

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain

Tristan E Rose et al. J Med Chem. .

Abstract

1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52) showed a 7-fold increase in potency, a 65-fold increase in C(max), and a 3300-fold increase in AUC over its adamantane analogue 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea (2). This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mechanical withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The soluble epoxide hydrolase inhibitor 52 (sEHi) reduces local inflammatory pain at a far lower dose than morphine. The inflammatory agent carrageenan was administered at time 0 resulting in a stable hyperalgesic response for the duration of the experiment. Zero time points represent normal response to pain. Treatment at 180 minutes post carrageenan with either morphine or compound 52 reversed symptoms. Standard deviation represents the average of 6 animals with regard to mechanical withdrawal threshold.
Scheme 1
Scheme 1
Synthesis of N-propionyl piperidine analogues Reaction conditions: (a) triphosgene, DCM, sat. NaHCO3 or 1N NaOH, sat. NaCl, 0 °C, 10min; (b) 4-nitrophenyl chloroformate, Et3N, THF, 0 to 50 °C, 1-3h; (c) 1, THF, 0 °C to rt, 1-24h; (d) 1, DMF, 70 °C, 4h.
Scheme 2
Scheme 2
Synthesis of N-acyl and N-sulfonyl piperidine analogues Reagents and conditions: (a) 1-BOC-4-aminopiperidine, THF, 0 °C to rt, 12h; (b) 1N HCl in MeOH, reflux, 3h; (c) R1SO2Cl, Et3N, THF, 0 °C to rt, 12h; (d) EDCI, R2COOH, DMAP, DCM, rt, 12-24h.

Similar articles

Cited by

References

    1. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res. 2004;43:55–90. - PubMed
    1. Moghaddam MF, Grant DF, Cheek JM, Greene JF, Williamson KC, Hammock BD. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med. 1997;3:562–566. - PMC - PubMed
    1. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA. 2005;102:9772–9777. - PMC - PubMed
    1. Yu ZG, Xu FY, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res. 2000;87:992–998. - PubMed
    1. Iliff JJ, Alkayed NJ. Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent. Future Neurol. 2009;4:179–199. - PMC - PubMed

Publication types

MeSH terms